Antibody-mediated rejection following renal transplantation

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 7, 2007, Pages 913-921

  Sureshkumar, Kalathil K ^a   Hussain, Sabiha M ^a   Carpenter, Barbara J ^a   Sandroni, Stephen E ^a   Marcus, Richard J ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Antibody mediated rejection; C4d staining; Humoral rejection; Renal transplantation

Indexed keywords

COMPLEMENT COMPONENT C4D; HLA ANTIBODY; IMMUNOGLOBULIN; LYMPHOCYTE ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAPHYLOCOCCUS PROTEIN A; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; ANTIBODY;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ANTIBODY PRODUCTION; BIOPSY TECHNIQUE; BLOOD GROUP TYPING; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; COMPLEMENT INHIBITION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; DRUG RESPONSE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; IMMUNOADSORPTION; IMMUNOHISTOCHEMISTRY; KIDNEY TRANSPLANTATION; MONOTHERAPY; PLASMAPHERESIS; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPLENECTOMY; SURVIVAL TIME; THROMBOSIS; HISTOCOMPATIBILITY; IMMUNOLOGY;

ANTIBODIES; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; RISK FACTORS; TRANSPLANTATION IMMUNOLOGY;

EID: 34249735337     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.7.913     Document Type: Review

References (37)

1. MAUIYYEDI S, COLVIN RB: Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr. Opin. Nephrol. Hypertens. (2002) 11(6):609-618.
2. WILLIAM GM, HUME DM, HUDSON JRP et al.: 'Hyperacute' renal homograft rejection in man. N. Engl. J. Med. (1968) 279:611.
3. MONTGOMERY RA, ZACHARY AA, RACUSEN LC et al.: Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match positive recipients. Transplantation (2000) 70(6):887-895
4. MONTGOMERY RA, HARDY MA, JORDAN SC et al.: Consensus opinion from the antibody-working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation (2004) 78(2):181-185.
5. MOLL S, PASCUAL M: Humoral rejection of organ allografts. Am. J. Transplant. (2005) 5:2611-2618.
6. RACUSEN LC, COLVIN RB, SOLEZ K et al.: Antibody-mediated rejection criteria - an addition to the Banff '97 classification of renal allograft rejection. Am. J. Transplant. (2003) 3:708-714.
7. RACUSEN LC, HALLORAN PF, SOLEZ K: Banff 2003 meeting report: new diagnostic insights and standards. Am. J. Transplant. (2004) 4:1562-1566.
8. FEUCHT HE, FELBER E, GOKEL MJ et al.: Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin. Exp. Immunol. (1991) 86(3):464-470.
9. FEUCHT HE, OPELZ C: The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int. (1996) 50(5):1464-1475.
10. FEUCHT HE: Complement C4d in graft capillaries - the missing link in the recognition of humoral alloreactivity Am. J. Transplant. (2003) 3(6):646-652.
11. VONGWIWATANA A, TASANARONG A, HIDALGO LG, HALLORAN PF: The role of B cells and alloantibody in the host response to human organ allografts. Immunol. Rev. (2003) 196:197-218.
12. REGELE H, BOHMIG GA, HABICHT A et al.: Capillary deposition of complement split product C4d in renal allograft is associated with basement membrane injury in peritubular and glomerular capillaries. J. Am. Soc. Nephrol. (2002) 13:2371-2380.
13. MAUIYYEDI S, CRESPO M, COLLINS AB et al.: Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J. Am. Soc. Nephrol. (2002) 13(3):779-787.
14. GIBNEY EM, CAGLE LR, FREED B et al.: Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol. Dial. Transplant. (2006) 21:2625-2629.
15. VESILESCU ER, HO EK, COLOVAI AI et al.: Alloantibodies and the outcome of cadaver kidney allografts. Human Immunol. (2006) 67:597-604.
16. TERASAKI PI, OZAWA M: Predicting kidney graft failure by HLA antibodies: a prospective trial. Am. J. Transplant. (2004) 4:438-443.
17. LEE PC, TERASAKI PI, TAKEMOTO SK et al.: All chronic rejection failures of kidney transplants preceded by development of HLA antibodies. Transplantation (2002) 74:1192-1194.
18. WORTHINGTON JE, MARTIN S, AL-HUSSEINI DM, DYER PA, JOHNSON RWG: Post-transplant production of donor HLA specific antibodies as a predictor of renal transplant outcome. Transplantation (2003) 75:1034-1040.
19. CRESPO M, PASCUAL M, TOLKOFF-RUBIN N et al.: Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation (2001) 71(5):652-658.
20. ROCHA PN, BUTTERLY DW, GREENBERG A et al.: Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation (2003) 75(9):1490-1495.
21. PASCUAL M, SAIDMAN S, TOLKOFF-RUBIN N et al.: Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation (1998) 66(11):1460-1464.
22. SHAH A, NADASDY T, AREND L et al.: Treatment of C4d positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation (2004) 77(9):1399-1405.
23. JORDAN S, CUNNINGHAM-RUNDLES C, MCEWAN R: Utility of intravenous immune globulin in kidney transplantation: efficacy safety, and coast implications. Am. J. Transplant. (2003) 3(6):653-664.
24. JORDAN S, VO AA, PENG A, TOYODA M, TYAN T: Intravenous gammaglobulin (IV): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am. J. Transplant. (2006) 6:459-466.
25. WHITE NB, GREENSTEIN SM, CANTAFIO AW et al.: Successful rescue therapy with plasmapheresis and IVIG for acute humoral renal transplant rejection. Transplantation (2004) 78(5):772-774.
26. BOHMIG GA, WAHRMANN M, REAGELE H et al.: Immunoadsorption in severe C4d positive acute kidney allograft rejection. Am. J. Transplant. (2006) 6:1-5.
27. JI SM, LI LS, CHEN JS et al.: Novel rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate moferil for Cd4 positive acute humoral renal allograft rejection. World Transplant Congress. Boston, USA (22-27 July 2006) Abstr. 1275.
28. KIMBALL JA, PESCOVITZ MD, BOOK BK, NORMAN DJ: Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation (1995) 60(12):1379-1383.
29. BECKER YT, BECKER BN, PIRSCH JD, SOLLINGER HW: Rituximab as treatment for refractory kidney transplant rejection. Am. J. Transplant. (2004) 4(6):996-1001.
30. WEINTRAUB LA, ZARKHIN V, SARWAL MM: Efficacy and safety of rituximab for treatment of recalcitrant acute renal allograft rejection. World Transplant Congress. Boston, USA (22-27 July 2006) Abstr. 1723.
31. CRESPO M, AROSTEGUI J, LOZANO M et al.: Risk factors to determine the need of rituximab for refractory acute humoral rejection after kidney transplantation. World Transplant Congress. Boston, USA (22-27 July 2006) Abstr. 1719.
32. VONGWIWATANA A, GOURISHANKAR S, CAMPBELL PM, SOLEZ K, HALLORAN PF: Peritubular capillary changes and c4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. Am. J. Transplant. (2004) 4:124-129.
33. SIS B, MUELLER T, CAMPBELL P et al.: Transplant glomerulopathy, late antibody mediated rejection, and the ABCD tetrad. World Transplant Congress. Boston, USA (22-27 July 2006) Abstr. 1196.
34. MAUIYYEDI S, PELLE PD, SAIDMAN S et al.: Chronic humoral rejection: identification of antibody-mediated chronic renal allograft I rejection by C4d deposits in peritubular capillaries. J. Am. Soc. Nephrol. (2001) 1(3):574-582.
35. THERUVATH TP, SAIDMAN SL, MAUIYYEDI S et al.: Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation (2001) 72(1):77-83.
36. CARDELLI F, PASCUAL M, TOLKOFF-RUBIN N et al.: Prevalence and significance of anti-HLA and donor specific antibodies long-term after renal transplantation. Transpl. Int. (2005) 18:532-540.
37. MENGEL M, BOGERS J, BOSMANS JL et al.: Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am. J. Transpl. (2005) 5:1050-1056.